HPV DNA + LBC Co-Tests Promotion.

Price from RM 340.

• Sample Requirements - Cervical broom & SurePath vial.
• LTAT (upon sample received) - 3 working days.

Test Results Cover

• Gynaecological cytology - SurePath PAP Test.
• Human Papillomavirus DNA - High risk HPV genotypes.
• Low risk HPV genotypes.

Co-testing with HPV DNA and Liquid-Based Cytology (LBC) represents a significant advancement in cervical cancer screening. Compared to conventional Pap smears, LBC offers improved sensitivity and specificity, providing a clearer, monolayered smear that reduces the risk of underdiagnosis.

According to the studies reviewed by the Malaysia Health Technology Assessment Section (MaHTAS), combining HPV testing with LBC boosts detection rates to an impressive 98% outperforming the 91-94% rate of a single test. Given the prevalence of false-negative reports with Pap smears have been reported to range from 6% to 50%, accurate identification of abnormal cells is paramount for early intervention and prevention of cervical cancer.

It is therefore imperative that healthcare providers recommend co-testing with HPV and LBC for women aged 30 and above on a yearly basis. Innoquest Pathlogy embraces this innovative approach to ensure more prescise and comprehensieve screening for cervical abnormalities, ultimately promoting the health and well-being of our patients.